FDA
-
-
-
-
-
-
-
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Beam Therapeutics reaches FDA alignment on accelerated approval pathway
-
-
-
-
-
-
-
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
-
-
-
-
-
-
-
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
-
-
-
-
-
-
-
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
-
327,753 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

